Pre-clinical investigation of liquid sirolimus for local drug delivery

被引:3
|
作者
Todd, Meagan [1 ]
Liu, Linda B. [1 ]
Saul, Justin M. [2 ]
Yazdani, Saami K. [1 ]
机构
[1] Wake Forest Univ, Dept Engn, Winston Salem, NC 27109 USA
[2] Miami Univ, Dept Chem Paper & Biomed Engn, Oxford, OH USA
来源
FRONTIERS IN CARDIOVASCULAR MEDICINE | 2023年 / 10卷
关键词
sirolimus; liquid; ex vivo; pharmacokinetics; drug delivery; peripheral arterial disease; delivery device; BALLOON; PACLITAXEL; ANGIOPLASTY; RESTENOSIS; REGULATORS; RESPONSES; RAPAMYCIN; MODEL;
D O I
10.3389/fcvm.2023.1184816
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Sirolimus is currently being explored as an alternative drug to paclitaxel for the treatment of peripheral artery disease (PAD). To date, sirolimus has only been used as drug coatings for stents and balloons and no studies have yet demonstrated the delivery of sirolimus in liquid form. The purpose of this pilot study was to investigate the feasibility of the delivery of liquid sirolimus into arterial segments in a benchtop peripheral artery bioreactor.Methods: The feasibility to deliver liquid therapy was first tested on four drug delivery devices using a fluorescently tagged liquid drug and an ex vivo porcine artery benchtop model. The four devices included the Bullfrog micro-infusion device, ClearWay RX catheter, Occlusion perfusion catheter (OPC), and the targeted adjustable pharmaceutical administration system (TAPAS). Penetration of the fluorescently tagged drug was measured via microscopic imaging and quantification of the depth of drug penetration into all device-treated tissue. Based on the penetration outcome, we then selected a single device to deliver liquid sirolimus into the ex vivo porcine artery model undergoing physiological flow and pressure conditions. The liquid sirolimus-treated arteries were collected from the ex vivo bioreactor at 1- and 24-hour post-delivery and arterial drug retention analyzed by liquid chromatography-tandem mass spectrometry.Results: Fluorescent microscopy demonstrated that drug delivery with the OPC had greater drug penetration into the medial wall as compared to other devices (OPC: 234 +/- 161 mu m; TAPAS: 127 +/- 68 mu m; ClearWay: 118 +/- 77 mu m; Bullfrog: 2.12 +/- 3.78 mu m; p = 0.098). The results of the ex vivo flow-circuit bench top model showed that the OPC device successfully delivered the liquid sirolimus at 1-hour (5.17 +/- 4.48 ng/mg) and 24-hour (0.78 +/- 0.55 ng/mg).Conclusions: These results demonstrate for the first time the ability to deliver liquid sirolimus directly to the medial layer of an artery via a liquid delivery catheter.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Review of ultrasound mediated drug delivery for cancer treatment: updates from pre-clinical studies
    Couture, Olivier
    Foley, Jessica
    Kassell, Neal F.
    Larrat, Benoit
    Aubry, Jean-Francois
    TRANSLATIONAL CANCER RESEARCH, 2014, 3 (05) : 494 - 511
  • [22] Sulfamates in drug design and discovery: Pre-clinical and clinical investigations
    Zaraei, Seyed-Omar
    Abduelkarem, Abduelmula R.
    Anbar, Hanan S.
    Kobeissi, Sara
    Mohammad, Miami
    Ossama, Aya
    El-Gamal, Mohammed I.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 179 : 257 - 271
  • [23] Positron Emitting Tracers in Pre-Clinical Drug Development
    Fernandes, E.
    Barbosa, Z.
    Clemente, G.
    Alves, F.
    Abrunhosa, A. J.
    CURRENT RADIOPHARMACEUTICALS, 2012, 5 (02) : 90 - 98
  • [24] Pre-clinical abuse testing applications in drug development
    Randall-Thompson, Jovita
    Klein, Michael
    DRUG AND ALCOHOL DEPENDENCE, 2017, 171 : E173 - E173
  • [25] Tight binding enantiomers of pre-clinical drug candidates
    Evans, Gary B.
    Cameron, Scott A.
    Luxenburger, Andreas
    Guan, Rong
    Suarez, Javier
    Thomas, Keisha
    Schramm, Vern L.
    Tyler, Peter C.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (17) : 5326 - 5333
  • [26] PRE-CLINICAL DRUG SCREEN IN A PDX ETMRMOUSE MODEL
    Schmidt, Christin
    Schubert, Nil A.
    Mack, Norman
    Chan, Jennifer A.
    Korshunov, Andrey
    Pfister, Stefan
    Kool, Marcel
    NEURO-ONCOLOGY, 2016, 18 : 143 - 143
  • [27] Mouse models for pre-clinical drug testing in leukemia
    Bhatia, Sanil
    Daschkey, Svenja
    Lang, Franziska
    Borkhardt, Arndt
    Hauer, Julia
    EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (11) : 1081 - 1091
  • [28] PRE-CLINICAL EVALUATION OF DRUG EFFECTS ON TESTICULAR FUNCTIONS
    NEUMANN, F
    SCHENCK, B
    PHARMACOLOGY & THERAPEUTICS, 1979, 5 (1-3) : 345 - 359
  • [29] Transdermal delivery of artemisinins for treatment of pre-clinical cerebral malaria
    Zech, Johanna
    Dzikowski, Ron
    Simantov, Karina
    Golenser, Jacob
    Maeder, Karsten
    INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE, 2021, 16 : 148 - 154
  • [30] Pharmacokinetic Drug Interactions of Piperine: A Review of Pre-clinical and Clinical Studies
    Najar, Imtiyaz Ahmed
    Pamu, Sagar
    Paul, Anushka
    Arora, Poonam
    Kaur, Gaganjit
    Kumar, Manish
    CURRENT DRUG METABOLISM, 2024,